Market Research Report
Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes (Insulin, Glucagon-Like Peptide-1), Growth Hormone Therapy, Osteoporosis, Fertility), End User (Homecare and Hospitals), and Region - Global Forecast to 2022
|Published by||MarketsandMarkets||Product code||608818|
|Published||Content info||138 Pages
|Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes (Insulin, Glucagon-Like Peptide-1), Growth Hormone Therapy, Osteoporosis, Fertility), End User (Homecare and Hospitals), and Region - Global Forecast to 2022|
|Published: February 27, 2018||Content info: 138 Pages||
The global injection pen market is expected to reach USD 41.38 billion by 2022 from an estimated USD 30.97 billion in 2017, at a CAGR of 6.0% during the forecast period. Growing prevalence of chronic diseases across the globe, increasing number of regulatory approvals, and favorable reimbursements are expected to drive the growth of the injection pen market. However, preference for alternative drug delivery modes and poor reimbursement scenario in developing countries is expected to restrain the growth of this market to a certain extent.
Based on type, the market is segmented into disposable and reusable injection pens. The disposable injection pens segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the benefits that these pens offer, such as portability, ease of use, and a lower possibility of infection.
Based on therapy, the global injection pen market is segmented into diabetes, growth hormone therapy, osteoporosis, fertility, and other therapies. The diabetes segment is expected to grow at the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the large diabetic population and favorable reimbursements for diabetic treatments in developed countries. The diabetes segment is further segmented into Insulin and GLP-1.
North America is expected to witness the highest growth during 2017 to 2022. The highest growth rate of the North American market is attributed to the rising prevalence of diabetes in the US and Canada, a favorable reimbursement scenario, and the increasing number of awareness programs in that region.
Break of primary participants was as mentioned below:
The key players in the global injection pen market are Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), Merck (US), Ypsomed (Switzerland), AstraZeneca (UK), F.Hoffman-La Roche (Switzerland), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), Pfizer (US), and Haselmeier (Switzerland).
The report analyzes the injection pen market and aims at estimating the market size and future growth potential of this market based on various segments such as type, therapy, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned five strategies.
This report provides insights into the following pointers:
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.